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Abstract	
Stabilizing	biomolecular	interactions	with	synthetic	molecules	to	impact	biological	function	is	a	
concept	of	enormous	appeal.	Although	much	effort	has	been	devoted	to	disrupting	protein-
protein	interactions	(PPIs)	using	inhibitors,	less	attention	has	been	directed	toward	the	reverse	
strategy,	that	of	inducing	new	PPIs.	However	recent	years	have	seen	a	resurgence	of	interest	in	
designing	molecules	that	bring	proteins	together.	This	approach	promises	to	significantly	expand	
the	range	of	tractable	targets	for	chemical	biology	and	therapeutic	intervention.	Pioneering	
structural	and	biophysical	investigation	of	ternary	complexes	formed	by	mono-	and	bifunctional	
ligands	highlight	that	proximity-induced	stabilization	or	de	novo	formation	of	PPIs	are	a	common	
feature	of	their	molecular	recognition.	In	this	review,	we	illustrate	these	concepts	and	advances	
with	representative	case	studies,	and	highlight	progress	over	the	past	three	years,	with	particular	
focus	on	recruitment	to	E3	ubiquitin	ligases	by	“molecular	glues”	and	chimeric	dimerizers	
(PROTACs)	for	targeted	protein	degradation.	
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Introduction	
Protein-protein	interactions	(PPIs)	mediate	most	intracellular	processes,	so	it	is	not	surprising	that	
modulation	of	PPIs	using	small	molecules	is	one	of	the	“holy	grails”	of	pharmacology	and	chemical	
biology	 [1] .	Despite	 the	often	 large	and	 flat	 interfaces	of	protein	complexes,	 recent	years	have	
witnessed	 progress	 in	 developing	 small-molecule	 probes	 and	 drugs	 that	 disrupt	 PPIs	 with	 high	
binding	 affinity	 and	 selectivity,	 and	 suitable	 pharmacokinetic	 properties,	 reviewed	 elsewhere	
[2,3] .	 	An	opposite	strategy	has	fascinated	scientists	for	decades:	stabilizing	or	forming	de	novo	
PPIs	 with	 interfacial	 molecules,	 also	 called	 “molecular	 glues”	 [4,5] .	 By	 bringing	 together	 two	
proteins	 that	would	not	normally	 interact,	 control	 can	be	 gained	 in	principle	over	protein	 fate,	
localization	 and	 function,	 impacting	 cellular	 signalling	 [6] .	 Bifunctional	 chimeric	 molecules,	
composed	of	 two	binding	units	often	 referred	 to	as	chemical	 inducers	of	dimerization	 (CIDs)	or	
chemical	 inducers	 of	 proximity	 (CIPs),	 enable	 recruitment	 of	 two	 targets	 simultaneously	 [7,8] .	
Dimerization	 can	 be	 for	molecules	 of	 the	 same	 protein	 (homo-dimerizer)	 or	 different	 proteins	
(hetero-dimerizer).	 Formation	 of	 the	 desired	 ternary	 complex	 is	 more	 productive	 when	 the	
dimerizer	 binds	 one	 protein	 more	 tightly	 in	 the	 presence	 of	 the	 other	 protein	 rather	 than	 its	
absence	–	a	thermodynamic	characteristics	of	ternary	equilibria	known	as	cooperativity	[9-12] .	
	
Chemical	inducers	of	dimerization	
Molecules	that	function	as	CIDs	are	found	 in	Nature.	Amongst	natural	CIDs	are	complex	natural	
products	 that	 have	 macrocyclic	 structures,	 such	 as	 rapamycin,	 cyclosporine	 A,	 and	 the	
immunosuppressive	 drug	 FK506	 (tacrolimus)	 (Figure	 1a).	 These	 molecules	 exert	 their	
immunosuppressant	 activity	 by	 recruiting	 immunophilins,	 such	 as	 the	 FK506	 binding	 protein	
FKBP12,	 to	 form	a	 ternary	 complex	with	a	 second	 target	protein.	 In	 the	 case	of	 rapamycin	and	
cyclosporine/FK506	the	recruited	proteins	are	mTOR	and	calcineurin,	respectively,	and	as	a	result	
of	 the	 induced	 dimerization	 the	 activity	 of	 the	 target	 is	 inhibited	 [13] .	 Crystal	 structures	 of	
ternary	 complexes	 FKBP12:rapamycin:mTOR	 (FRB	 domain)	 [14] ,	 and	 FKBP12:FK506:calcineurin	
[15] 	 elucidated	 the	 structural	 basis	 for	 the	 molecular	 recognition	 (Figure	 1b).	 Biophysical	
investigation	of	 the	 thermodynamics	of	 the	 ternary	equilibria	 revealed	 that	 rapamycin	binds	 to	
mTOR	with	2000-fold	enhanced	binding	affinity	when	pre-bound	to	FKBP12,	hence	exhibits	high	
cooperativity	 [16] .	 These	 discoveries	 were	 taken	 a	 step	 further	 by	 developing	 synthetic	
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bifunctional	 ligands	 that	 can	 be	 used	 to	 control	 the	 intracellular	 oligomerization	 of	 specific	
proteins.	Early	work	on	a	dimer	of	FK506,	called	FK1012	(Figure	1a),	artificially	promoted	FKBP12	
homodimerization	[17] .	More	recently,	Shokat	and	colleagues	developed	bifunctional	molecules	
that	 recruit	 the	 cancer	 target	 Ras	 in	 a	 tripartite	 complex	 with	 FKBP12	 and	 cyclophilin	 A	 as	 a	
strategy	to	interfere	with	Ras	activity	and	block	its	downstream	signaling	pathway	[18] .	
	
	
Figure	1.	Chemical	Inducers	of	Dimerization	(CIDs).	a)	Chemical	structures	of	natural	and	synthetic	CIDs.	b)	
Crystal	structures	of	cooperative	ternary	complexes	formed	by	rapamycin	(top,	PDB	code	1FAP	[14])	and	
FK-506	(bottom,	PDB	code	1TCO	[15]).	
	
	
Monovalent	PPI	stabilisers	
Nature	 also	 exploits	 endogenous	 ligands	 and	 cofactors	 to	 stabilize	 native	 interactions	 with	
physiological	consequences.	 	Serendipitous	discoveries	have	unveiled	surprisingly	simple	natural	
compounds,	 conceptually	 monovalent,	 that	 form	 de	 novo	 protein-protein	complexes.	 Plant	
hormones	 auxin	 and	 jasmonate	 bind	 to	 specific	 E3	 Cullin	 RING	 ligases	 (CRLs)	 and	 promote	
recruitment	 of	 neo-substrates	 via	 a	 ligand-dependent	 degron	 mechanism	 [19,20] .	 The	 PPI-
stabilizing	 feature	of	 small	molecules	 is	however	not	 limited	 to	natural	ones:	 it	 is	 critical	 to	 the	
pharmacological	activity	of	synthetic	molecules	too.	For	example,	the	 immunomodulatory	drugs	
(ImIDs)	thalidomide	and	its	analogues	pomalidomide,	lenalidomide	and	CC-885	(Figure	2a-c)	exert	
their	anti-cancer	and	 immunosuppressant	activity	by	binding	to	cereblon	(CRBN),	 the	substrate-
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recognition	subunit	of	the	CRL4ACRBN	E3	ligase	complex	[21-23] .	ImIDs	act	as	CRBN	modulators	to	
aid	recruitment	of	 ‘neo-substrate’	proteins	 including	the	transcription	 factors	 Ikaros	 (IKZF1)	and	
Aiolos	 (IKZF3),	 CK1α,	 and	 GSPT1.	 These	 neo-substrates	 form	 tight	 complexes	 with	 varying	
specificies	 for	different	CRBN:ligand	complexes,	ultimately	 leading	to	neo-substrate	degradation	
[21,22,24,25] .	More	recently,	neo-substrate	SALL4	has	been	identified	as	the	target	responsible	
for	 the	 infamous	 theratogenicity	 of	 thalidomide	 [26,27] .	 Pioneering	 structural	 studies	 by	 the	
groups	 of	 Thoma	 and	 Chamberlain	 have	 elucidated	 the	 structural	 basis	 of	 the	 ImID-induced	
recruitment	of	neo-substrates	to	CRBN	[28,29] .	The	ImID-dependent	degron	was	revealed	to	be	
a	tight	hairpin	loop	present	in	many	zinc	finger	proteins,	that	has	exquisite	structurally-conserved	
features	despite	low-sequence	conservation	across	the	neo-substrates	[30] 	(Figure	2a-c).	
	
Plant	hormones	and	ImiDs	are	notable	examples	of	small	molecules	that	bind	to	an	E3	ligase	and	
“hijack”	 its	 activity	 toward	 a	 new	 protein.	 However,	 a	 small	 molecule	 may	 also	 increase	
ligase:substrate	 binding	 affinity	 that	 may	 have	 been	 weakened,	 for	 example	 as	 a	 result	 of	
mutations,	 by	 stabilizing	 PPIs	 between	 the	 E3	 and	 its	 natural	 substrate.	 If	 these	mutations	 are	
involved	 in	disease,	 rescuing	weakened	 interactions	with	such	“molecular	glues”	could	open	up	
new	 therapeutic	 opportunities.	 This	 strategy	 was	 recently	 applied	 by	 a	 team	 at	 Nurix	 Inc.	 to	
stabilize	the	interaction	between	the	E3	ligase	SCFβ-TRCP	and	its	natural	substrate	β-catenin	[31] .	
This	PPI	is	weakened	as	a	result	of	cancer-driving	mutations	on	the	phospho-degron	of	β-catenin,	
that	prevent	phosphorylation	events	crucial	to	formation	of	the	native	PPI.	Crystal	structure	of	β-
TRCP	 in	 complex	 with	 NRX-103094	 and	 a	 β-catenin-degron	 mutant	 peptide	 revealed	 the	
compound	bound	snugly	at	the	protein-peptide	interface,	with	its	trifluoromethylpyridone	group	
occupying	 a	 pocket	 revealed	 by	 the	 β-catenin	 mutation	 and	 forming	 tight	 hydrophobic	
interactions	with	both	proteins	to	stabilize	the	ternary	complex	[31] 	(Figure	2d).	
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Figure	2.	Molecular	glues	of	E3	ubiquitin	ligases.	a-c)	Co-crystal	structures	of	ternary	complexes	
CRBN:pomalidomide:Ikaros	(a,	PDB	code	6H0F	[30]),	CRBN:lenalidomide:CK1α	(b,	PDB	code	5FQD	[28]),	
and	CRBN:CC-885:GSPT1	(c,	PDB	code	5HXB	[29])	illustrate	the	range	of	binding	modes	for	neo-substrate	
recruitment	accommodated	by	the	different	ImID	compounds.	The	structurally-conserved	β-hairpin	loop	
that	function	as	ligand-dependent	neo-substrate	degron	is	highlighted.	d)	Co-crystal	structure	of	ternary	
complex	β-TRCP:NRX-103094:β-catenin	(PDB	code	6M91	[31]).	
	
Other	notable	examples	of	PPI	stabilizers,	beyond	E3	ligases,	are	small	molecules	that	strengthen	
the	interaction	between	14-3-3	proteins	and	their	cognate	substrate	partners,	reviewed	
elsewhere	[5,32] .	In	a	recent	study,	Sijbesma	et	al.	applied	cysteine-targeting	site-directed	
fragment	screening	to	discover	orthosteric	stabilizers	of	the	14-3-3:ERα	interaction	[33] .	
	
While	prominent	examples,	the	compounds	described	so	far	either	bind	preferentially	to	only	one	
of	 the	 two	 proteins	 in	 the	 complex,	 or	 bind	 weakly	 to	 the	 individual	 components,	 and	 show	
measurable	binding	affinity	only	as	part	of	a	fully	formed	complex.	This	means	that	even	when	a	
first	 protein-ligand	 pair	 is	 identified,	 there	 is	 little	 control	 on	 which	 second	 target	 can	 be	
recruited.	The	target	scope	can	be	expanded	conceptually	by	designing	bifunctional	molecules.	
	
Bivalent	inhibitors	
Bivalent	inhibitors	can	engage	two	molecules	of	target	protein	simultaneously,	thereby	potentially	
aiding	pharmacological	potency	due	to	an	avidity	effect.	Illendula	et	al.	developed	compound	AI-
10-49,	a	bivalent	inhibitor	of	the	PPI	between	transcription	factors	CBFβ-SMMHC	(fusion	of	core	
binding	 factor	 b	 and	 smooth-muscle	 myosin	 heavy	 chain)	 and	 RUNX1,	 which	 sustains	 acute	
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myeloid	 leukemia	 (AML)	 growth.	 AI-10-49	 was	 significantly	 more	 potent	 that	 the	 parent	
monovalent	 compound,	 displayed	 favourable	 pharmacokinetics,	 and	 delayed	 leukemia	
progression	in	mice	[34] .		
	
	
Figure	3.	Bivalent	BET	inhibitors.	Crystal	structures	of	avid	ternary	complexes	formed	by	MT1	(a,	PDB	code	
5JWM	[35])	and	Bi-BET	(b,	PDB	code	5AD3	[36])	with	two	protomers	of	the	first	bromodomain	of	Brd4	
(Brd4BD1).	
	
Two	groups	at	Dana-Farber	[35] 	and	AstraZeneca	[36] 	reported	bivalent	inhibitors	of	the	bromo	
and	extraterminal	domain	(BET)	proteins	Brd2,	Brd3	and	Brd4	(Figure	3).	Most	BET	inhibitors	such	
as	 the	 archetypical	 JQ1	 and	 IBET-762,	 bind	 to	 BET	 proteins	 monovalently	 by	 targeting	 their	
bromodomain.	 A	 bivalent	 approach	 to	 small-molecule	 inhibition	 stood	 as	 an	 attractive	
opportunity	for	this	target	class,	because	all	BET	proteins	contain	two	distinct	bromodomains	at	
their	 N-terminal	 region,	 termed	 BD1	 and	 BD2	 [37][38] .	 Both	MT1	 [35] 	 and	 biBETs	 [36,39] 	
were	 found	 to	bind	 intramolecularly	 two	domains	of	 a	 single	BET	protein.	 Co-crystal	 structures	
and	 allied	 biophysical	 studies	 evidenced	 the	 inhibitors	 bridging	 across	 two	 molecules	 of	
bromodomains	 and	 inducing	 extensive	 intermolecular	 PPIs	 [35,36] 	 (Figure	 3).	 In	 MT1,	 two	
molecules	of	JQ1	are	joined	together	using	a	linker	length	of	7	ethylene	glycol	units	(PEG-7	linker)	
(Figure	 3a).	 MT1	 was	 found	 to	 be	 100-fold	 more	 potent	 than	 the	 corresponding	 monovalent	
inhibitor	JQ1	at	blocking	Brd4	from	binding	to	chromatin	in	cells	[35] .	BiBET,	initially	developed	
to	 downregulate	 androgen	 receptor	 signalling,	 was	 revealed	 to	 engage	 simultaneously	 two	
bromodomains	of	 a	BET	protein	 [36] 	 (Figure	3b).	Cells	 treated	with	 these	bivalent	 compounds	
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showed	inhibition	of	cell	growth	in	a	manner	consistent	with	sensitivity	to	BET	inhibition,	and	with	
a	remarkable	enhancement	in	potency,	consistent	with	strong	avidity	effects	[35,36] .	
	
Bifunctional	degraders:	Proteolysis-targeting	chimeras	(PROTACs)	
Conventional	genetic	techniques	to	knockdown	or	knockout	the	expression	level	of	proteins	have	
been	based	on	nucleic	acids,	for	example	antisense	oligonucleotides,	RNAi	and	siRNA,	and	more	
recently	CRISPR-Cas9	[40] .	A	small-molecule	approach	to	induce	intracellular	protein	degradation	
combines	 the	 desired	 output	 of	 knockdown	 techniques	 with	 favourable	 pharmacological	
properties	 of	 small	 molecules	 as	 well	 as	 acute,	 fast,	 selective	 and	 reversible	 effects.	 Such	
“chemical	degraders”	recruit	target	proteins	to	an	E3	ubiquitin	ligase,	thereby	inducing	selective	
target	 ubiquitination	 and	 degradation	 [41,42] .	 One	 prominent	 class	 of	 bifunctional	 chemical	
degraders	 are	 known	as	proteolysis-targeting	 chimeras	 (PROTACs)	 [43] .	 PROTACs	 contains	 two	
ligands,	one	for	a	target	protein	of	interest	and	one	for	an	E3	ligase,	connected	via	a	linker.	The	
historical	 backdrop	 and	 latest	 developments	 of	 PROTACs	 have	 been	 extensively	 reviewed	
elsewhere	[43-46] .	Here	we	briefly	outline	prominent	and	well-characterized	PROTAC	molecules	
described	 in	 2015	 [47] 	 and	 review	 recent	 structural	 work	 that	 have	 evidenced	 how	 PROTACs	
induce	protein-protein	interactions	within	their	ternary	complexes.	
	
The	 development	 of	 non-peptidic	 PROTACs	 with	 high	 cellular	 efficacies	 and	 specificities	 was	
ushered	by	the	discovery	of	two	low–molecular	weight,	specific,	high-affinity	E3	ligands,	namely	
VHL	 ligand	 VH032	 [48-50] 	 and	 the	 cereblon	 ligands	 (described	 above).	 These	 new	 E3	 ligands	
enabled	the	assembly	of	potent	and	selective	PROTACs	against	targeted	proteins	of	interest	[51-
54] .	 The	 first	 examples	 of	 PROTACs	 recruiting	 CRL2VHL	 to	 induce	 degradation	 of	 a	 target	were	
reported	in	mid-2015	by	our	laboratory	[51] 	and	the	Crews/GSK	laboratories	[52] .	Both	studies	
used	a	VHL	recruiting	moiety	of	relatively	small	size	(MW	=	472	Da)	and	high	binding	affinity	(Kd	=	
180	nM)	 for	a	 compound	 targeting	a	PPI	 site	 [49] .	 Zengerle	et	 al.	 linked	 the	pan-selective	BET	
inhibitor	 JQ1	 to	 the	VHL	 ligand	 via	 solvent-exposed	 regions	 using	 an	 optimized	 PEG-3	 linker	 to	
afford	MZ1	[51] 	(Figure	4a).	MZ1	qualified	as	a	potent,	fast	and	well-characterized	BET	PROTAC	
exerting	 preferential	 degradation	 of	 Brd4	 [51,55,56] .	 The	 same	 VHL	 ligand	 was	 linked	 to	
inhibitors	 for	the	serine/threonine	kinase	RIPK2	via	a	PEG-4	 linker	to	yield	PROTAC_RIPK2	[52] .	
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VHL-based	PROTACs	have	since	been	deployed	successfully	against	a	wide	array	of	target	proteins	
[44,45,57] .		
	
The	first	example	of	PROTACs	recruiting	CRL4CRBN	were	reported	around	the	same	time	as	the	VHL	
recruiting	PROTACs	by	the	Bradner	laboratory	(dBET1	[53])	and	Arvinas	(ARV-825	[54]).	Winter	
et	al.	coupled	JQ1	to	pomalidomide	to	obtain	dBET1	inducing	potent	degradation	of	BET	proteins	
[53] .	The	compounds	were	later	optimized	to	more	potent	BET	degrader	dBET6	[58] 	(Figure	4b).	
In	 a	 similar	 fashion,	 Lu	 et	 al.	 developed	 ARV825	 by	 coupling	 BET	 inhibitor	 OTX015	 (a	 close	
analogue	of	JQ1)	to	pomalidomide	via	a	short	alkyl	linker	[54] .		Both	VHL-based	and	CRBN-based	
BET	degraders	potently	and	 rapidly	 induce	 selective,	 reversible,	 and	 long-lasting	degradation	of	
BET	proteins	 in	a	proteasome-	and	E3	 ligase-dependent	fashion	 in	multiple	cancer	cell	 lines	and	
are	active	in	mouse	models	in	vivo	[58-61] .		
	
VHL	and	CRBN	ligands	have	also	been	conjugated	to	elements	recruiting	specific	tags	that	can	be	
fused	 to	 proteins	 of	 interest,	 leading	 to	 degradation	 of	 the	 tagged	 protein.	 Buckley	 et	 al.	
developed	conjugates	of	VHL	ligands	to	chloro-alkane	moieties	(HaloPROTACs)	and	studied	their	
ability	to	induce	the	degradation	of	transiently	expressed	proteins	fused	to	HaloTag7	[62] .	More	
recently,	Tovell	et	al.	qualified	HaloPROTAC-E,	a	conjugate	of	potent	VHL	inhibitor	VH298	[50] ,	as	
their	 most	 potent	 degrader	 of	 representative	 endosomal	 proteins	 endogenously	 Halo-tagged	
using	CRISPR-Cas9	[63] .	They	showed	that	HaloPROTAC-E	induced	rapid	(50%	protein	depletion	
in	30	minutes)	and	profound	depletion	(>95%)	of	target	protein,	retained	after	48	hours	[63] .	In	a	
similar	 fashion,	 Nabet	 et	 al.	 developed	 the	 CRBN-based	 system	 dTAG,	 by	 conjugating	 a	 CRBN	
ligand	to	a	bumped	ligand	for	a	mutant	FKBP12F36V	variant	[64] .	Unlike	RNAi	knockdowns,	these	
inducible-degron	technologies	are	highly	specific	at	post-translational	level,	can	be	developed	to	
have	little	to	no	off-target	effects,	and	allow	for	the	rapid	and	reversible	knockdown	of	any	gene	
of	interest	modified	with	suitable	fusion	tags	[65] .		
	
Structural	and	biophysical	insights	on	PROTACs	ternary	complexes	
An	important	step	forward	in	the	PROTAC	field	came	in	2017	with	the	first	description	of	a	crystal	
structure	revealing	how	a	PROTAC	binds	in	a	ternary	complex	[55] .	Using	X-ray	crystallography,	
Gadd	et	al.	 showed	that	MZ1,	when	anchoring	 the	 ternary	complex	VHL:MZ1:Brd4,	 induces	 the	
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formation	of	new	 interactions	between	VHL	and	the	Brd4	bromodomain	 (Figure	4a).	These	two	
proteins	do	not	 interact	with	any	measurable	binding	affinity	 in	 the	absence	of	 the	compound.	
The	structure	revealed	that	MZ1	 is	“sandwiched”	between	the	two	proteins,	 inducing	extensive	
de	novo	protein-protein	and	protein-ligand	contacts	of	both	hydrophobic	and	electrostatic	nature,	
which	 together	 bury	 >2600	 Å2	 of	 protein	 surface	 area,	 of	 which	 ~700	 Å2	 contributed	 by	 the	
induced	 PPI	 [55] .	 Allied	 biophysics	 and	 mutagenesis	 swap	 experiments	 revealed	 that	 the	 PPI	
gained	in	the	process	contribute	extra	stabilization	energy	to	the	complex	(>2	kcal/mol),	beyond	
the	sum	of	the	binary	binding	energies,	corresponding	to	>20-fold	increase	in	binding	affinity.	This	
cooperativity	greatly	increases	the	potency	of	the	PROTAC,	enhancing	the	stability	and	population	
of	the	ternary	complex,	driving	the	preferential	degradation	of	Brd4	[55] .	Guided	by	the	crystal	
structure,	degrader	AT1	with	enhanced	selectivity	for	Brd4	was	designed	via	a	novel	conjugation	
vector	out	of	the	VHL	ligand	[55] .	More	recently,	Roy	et	al.	extended	biophysical	investigation	of	
PROTAC	 ternary	 complexes	 to	 studying	 the	 kinetics	 of	 their	 formation	 and	 dissociation	 using	
surface	 plasmon	 resonance	 (SPR).	 By	 immobilising	 biotinylated	 E3	 ligase	 on	 a	 chip	 and	 flowing	
over	PROTAC	in	the	absence	or	presence	of	target	protein,	they	were	able	to	quantify	the	overall	
kinetics	of	the	ternary	complexes	formed	and	show	that	the	comparatively	more	stable	and	long-
lived	 ternary	 complex	 formed	 by	 MZ1	 with	 VHL	 and	 Brd4-BD2	 drive	 faster	 rates	 of	 protein	
degradation	in	cell	[66] .	
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Figure	4.	Bifunctional	degraders	(PROTACs).	a)	Crystal	structure	of	the	cooperative	ternary	complex	formed	
by	MZ1	with	VHL	and	the	second	bromodomain	of	Brd4	(Brd4BD2)	(PDB	code	5T35	[55]).	b)	Crystal	
structure	of	non-cooperative	ternary	complex	CRBN:dBET6:Brd4BD1	(PDB	code	6BOY	[67]).	c)	Crystal	
structures	of	the	cooperative	ternary	complexes	formed	by	PROTAC-1	(left)	and	PROTAC-2	(right)	with	VHL	
and	the	bromodomain	of	Smarca2	(Smarca2BD)	(PDB	codes	6HAY	and	6HAX,	respectively	[68] ),	which	
guided	the	design	of	potent	PROTAC	degrader	ACBI1	via	optimization	of	the	linker	conformation	and	
introduction	and	stabilization	of	a	π-π	stack	with	VHL	residue	Tyr98.	Note:	ACBI-1	and	PROTAC-2	differ	by	a	
single	oxygen	atom	in	the	linker.		
	
Unlike	 in	 the	 case	 of	 monovalent	molecular	 glues,	 formation	 of	 positively	 cooperative	 ternary	
complexes	 is	 not	 a	 strict	 requirement	 for	 productive	 targeted	 protein	 degradation.	 Already	 in	
2017,	Chan	et	al.	reported	another	series	of	VHL-based	BET	degraders	that	were	designed	using	
IBET-726,	a	more	potent	BET	inhibitor	than	JQ1,	via	a	different	conjugation	vector	than	JQ1	[69] .	
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This	strategy	led	to	negatively-cooperative	degraders,	that	form	ternary	complexes	that	dissociate	
comparatively	much	more	rapidly	than	MZ1	[66] .	In	spite	of	these	unfavourable	thermodynamics	
and	kinetics	 features	of	ternary	complex	formation,	Chan	et	al.	showed	that	PROTACs	based	on	
IBET-726	were	nevertheless	active	as	BET	degraders	[69] .	However,	interestingly,	they	exhibited	
different	 BET	 isoform	 degradation	 profiles,	 and	were	 found	 to	 behave	more	 as	 inhibitors	 than	
degraders	 at	 higher	 concentrations,	 consistent	 with	 their	 greater	 binary	 binding	 affinities,	
negative	 cooperativities	 and	 more	 pronounced	 hook	 effects	 [69] .	 Similarly,	 active	 PROTAC	
degraders	 for	 the	protein	kinase	BTK	were	developed	 that	were	also	 shown	 to	exhibit	negative	
cooperativity	 [70] .	 In	2018,	Nowak	et	al.	described	 the	co-crystal	 structure	of	CRBN-based	BET	
degrader	dBET6	in	complex	with	CRBN	and	Brd4-BD1	[67] 	(Figure	4b).	In	contrast	to	the	structure	
by	Gadd	et	al.,	 in	the	ternary	complex	structure	of	CRBN:dBET6:Brd4-BD1	no	obvious	additional	
hydrogen	bonds	were	observed	from	the	PROTAC,	and	a	lesser	buried	surface	area	was	observed	
[71,72] .	 The	 structural	 features	 were	 consistent	 with	 negative	 cooperativity	 for	 dBET6	 and	
related	 analogues	 observed	 in	 biophysical	 assays	 [67] .	 Despite	 the	 negative	 cooperativity	 of	
these	 systems,	 favorable	 PPI	 were	 induced	 by	 the	 PROTAC.	 This	 suggests	 other	 unfavorable	
energetic	 contributions,	 likely	 strain	 of	 the	 PROTAC	 linker	 conformation	 forced	 in	 the	 ternary	
complex,	 must	 compensate	 and	 overcome	 these	 PPIs	 to	 result	 in	 an	 overall	 negative	
cooperativity.	 More	 recently,	 a	 team	 at	 the	 University	 and	 Dundee	 and	 Boehringer	 Ingelheim	
developed	potent	degraders	for	the	BAF	complex	ATPase	subunits	SMARCA2	and	SMARCA4	using	
structure-based	PROTAC	design	[68] .	Farnaby	et	al.	used	a	high-resolution	crystal	structure	of	a	
weak	 and	 partial,	 yet	 cooperative,	 PROTAC	 bound	 to	 VHL	 and	 the	 SMARCA2	 bromodomain	 to	
guide	 further	 stabilization	 of	 the	 complex,	 achieving	 PROTAC	 AC-BI1	 which	 potently	 impacted	
cancer	cells	rendered	vulnerable	to	SMARCA2	knockdown	[68] .	
	
Together,	 these	 pioneering	 structural	 and	 biophysical	 studies	 highlight	 the	 importance	 of	 the	
ternary	 complex	 and	 its	 relevance	 as	 key	 intermediate	 species	 in	 the	 PROTAC	 mechanism	 of	
action	[55,66-68] .	They	also	underscore	the	advantage	of	the	catalytic,	sub-stoichiometric	mode	
of	action	of	PROTAC	degraders,	that	can	achieve	efficient	target	ubiquitination	and	proteasomal	
degradation	formation	even	in	cases	where	suboptimal	ternary	complex	formation	equilibria	are	
involved	 [56,67,69,70,73] .	 Increasing	 evidence	 suggests	 that	 improving	 ternary	 complex	
formation	 parameters	 is	 an	 important	 strategy	 for	 optimizing	 the	 cellular	 activity	 and	 desired	
properties	 of	 PROTACs.	 This	 can	 contribute	 to	 achieving	 single-target	 selectivity	 beyond	 binary	
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target	engagement,	and	is	likely	to	be	required	in	cases	where	ligand	binary	binding	affinities	are	
relatively	 weak	 [55,69,74-77] .	 Similarly,	 reliance	 on	 favorable	 ternary	 complex	 equilibria	 is	
expected	to	be	important	in	designing	occupancy-based	bifunctional	probes	that,	unlike	PROTACs,	
must	rely	on	stoichiometric	formation	of	ternary	complexes	to	trigger	a	cellular	response.	
	
Homo-PROTACs:	dimerizers	of	E3	ubiquitin	ligases	
Merging	the	concepts	of	CIDs	and	PROTACs,	in	2017	Maniaci	et	al.	first	showed	that	it	is	possible	
to	dimerize	an	E3	ubiquitin	ligase	using	double-headed	molecules	“homo-PROTACs”	as	a	strategy	
to	 induce	 E3	 ligase	 degradation	 in	 cells	 [78] .	 Bifunctional	 molecules	 were	 constructed	 of	 the	
same	VHL	ligand	(VH032	or	VH298),	connected	via	a	PEG	linker	in	both	symmetric	and	asymmetric	
fashions,	to	induce	CRL2VHL	dimerization.	The	best	degrader	identified,	symmetric	homo-PROTAC	
CM11	 (Figure	5a),	exhibited	high	cooperativity	 (∼20)	 for	VHL	dimerization	 in	vitro,	and	 induced	
VHL	degradation	at	concentrations	>100-fold	 lower	 than	the	binary	Kd,	consistent	with	 the	sub-
stoichiometric	 mode	 of	 action.	 This	 work	 qualified	 CM11	 as	 a	 fast,	 potent	 PROTAC	 inducing	
profound	and	prolonged	degradation	of	VHL	in	different	cell	 lines	[78] .	Subsequently,	the	same	
concept	 was	 applied	 by	 Steinebach	 et	 al.	 to	 develop	 homo-PROTACs	 for	 the	 CRL4CRBN	 ligase,	
leading	to	compound	15a	as	the	most	active	CRBN	degrader	[79] 	(Figure	5a).	Interestingly,	VHL	
and	 CRBN	 could	 also	 be	 productively	 hijacked	 against	 one	 another.	 In	 two	 parallel	 studies,	
Steinebach	 et	 al.	 [80] 	 and	 Girardini	 et	 al.	 [81] 	 designed	 and	 characterized	 VHL-CRBN	 hetero-
dimerizers	 CRBN-6-5-5-VHL	 and	 14a,	 respectively	 (Figure	 5a).	 Both	 PROTACs	 were	 found	 to	
preferentially	induce	CRBN	degradation	in	a	concentration	and	time	dependent	fashion	[80,81] .	
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Figure	5.	Unconventional	targeting	of	E3	ubiquitin	ligases	with	bifunctional	molecules.	a)	Chemical	
structures	of	homo-dimerizers	(homo-PROTACs)	and	hetero-dimerizers	of	the	E3	ubiquitin	ligases	VHL	and	
CRBN.	b)	Chemical	structures	of	covalent	PROTACs	recruiting	novel	E3	ligases	RNF4,	RNF114	and	DCAF16.	
	
Summary	and	Prospectus	
The	 past	 few	 years	 have	 witnessed	 a	 renaissance	 in	 the	 enticing	 concept	 of	 bringing	 proteins	
together	with	small	molecules,	and	growing	efforts	to	apply	it	as	a	strategy	to	modulate	protein’s	
intracellular	 function,	 stability	 and	 levels.	 In	 large	 part	 fueled	 by	 the	 meteoric	 resurgence	 of	
PROTACs,	designing	bifunctional	molecules	to	form	ternary	complexes	is	now	establishing	itself	as	
a	 field	 on	 its	 own.	 Fundamental	 structural	 and	 biophysical	 investigation	 of	 recent	 years	 have	
revealed	 that	 the	 molecular	 recognition	 process	 is	 much	 more	 sophisticated	 than	 previously	
assumed	 [9] .	 In	 all	 systems	 structurally	 defined	 so	 far,	 highlighted	 herein,	 these	 chimeric	
molecules	do	much	more	than	simply	bringing	two	proteins	into	proximity	with	each	other:	they	
induce	extensive	protein-protein	contacts	of	varying	degrees	of	buried	surface	area.	In	hindsight,	
this	is	perhaps	not	surprising	because	once	two	proteins	have	been	brought	into	proximity	there	
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exists	 significant	 inherent	 potential	 to	 aid	 interactions,	 as	 the	 entropic	 barrier	 to	 complex	
formation	has	already	been	largely	overcome.	This	feature	of	molecular	recognition	is	therefore	
likely	to	be	much	more	fundamental	and	general	than	was	previously	anticipated	for	this	class	of	
molecule.	 It	 is	 also	 becoming	 increasingly	 evident,	 particularly	 for	 PROTACs,	 how	 nuances	 in	
cooperativity,	stability,	half-lives	and	perhaps	geometry	of	ternary	complexes	can	play	important	
roles	 in	 defining	 the	 concentration-spectrum,	 target	 selectivity	 and	 time-dependency	 of	
compounds’	 activities	 in	 cells	 and	 in	 vivo.	 For	 example,	 high	 cooperativity	 alleviates	 the	 hook	
effect,	and	can	render	compound	mode	of	action	less	dependent	on	cellular	permeability/uptake.	
We	therefore	believe	that	these	emerging	principles	of	ternary	complex	recognition	are	ripe	for	
guiding	rational	structure-based	design	of	bifunctional	chemical	probe	and	therapeutics.		
	
What	 is	next	 for	 the	design	of	molecular	dimerizers?	Clearly,	bi-	or	multi-functional	 ligands	will	
inspire	creativity	for	tackling	challenging	and	relevant	biological	systems	that	can	be	bridged	via	
synthetic	molecules.	Notable	are	 systems	where	monovalent	 interactions	 can	be	weak	on	 their	
own,	 e.g.	 carbohydrate	 binding	 elements	 and	 cell	 surface	 receptors	 [82] ,	 and	 	where	multiple	
domains	 are	 available	 for	 multivalent	 recognition	 of	 post-translational	 modifications,	 such	 as	
chromatin	 binding	 proteins	 [83] .	 Finding	 compounds	 that	 induce	 cellular	 PPIs	 with	 functional	
consequences	 remains	 a	 historic	 challenge.	 To	 tackle	 this	 challenge,	 it	 will	 be	 important	 to	
develop	 relevant	 screening	 approaches,	 and	 expand	 the	 chemical	 space	 covered	 by	 current	
compound	 libraries.	 For	 PROTACs	 and	 molecular	 glues,	 expanding	 to	 new	 E3	 ubiquitin	 ligases	
beyond	VHL	and	CRBN	is	an	obvious	next	step.	Recent	efforts	are	directed	towards	identifying	and	
characterizing	more	 E3	CRLs	 that	 can	be	 chemically	 tractable	 for	 targeted	protein	 degradation.	
Complementary	approaches	involve	de-orphanizing	E3	ligases	with	new	non-covalent	ligands	and	
degron	peptides	[31,84-86],	and	modifying	covalently	nucleophilic	residues	e.g.	cysteines	on	the	
E3	protein	using	electrophilic	warheads	[87-89] 	(Figure	5b).	Beyond	PROTACs	and	the	targeting	
to	E3	ligases,	it	will	be	interesting	to	watch	the	range	of	combinations	being	exploited	to	recruit	
proteins	 on-demand	 for	 purposefully	 modulating	 cellular	 signaling.	 Recent	 approaches	 include	
designing	 conjugates	 that	 recruit	 nuclease	 enzymes	 to	 RNA	 (Ribotac)	 [90] 	 and	 that	 bring	
extracellular	proteins	 to	 cell	 surface	 lysosome	 targeting	 receptors	 to	 induce	 the	degradation	of	
secreted	 and	 membrane	 proteins	 [91,92] .	 As	 medicinal	 chemistry	 navigates	 chemical	 space	
beyond	 the	 Rule-of-five,	 and	 accepts	 and	 addresses	 the	 associated	 challenges,	 developing	
bifunctional	molecules	of	suitable	PK	properties	is	proving	more	feasible	than	previously	thought.	
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The	 advances	 and	 exciting	 recent	 developments	 outlined	 in	 this	 review	 together	 suggest	
generality	and	outline	fresh	opportunities	that	can	be	achieved	by	bringing	proteins	together	as	
powerful	means	to	control	or	endow	new	protein	function	with	small	molecules.	
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